Compass Therapeutics
CMPX
73 hedge funds and large institutions have $288M invested in Compass Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 24 closing their positions.
8% more capital invested
Capital invested by funds: $267M → $288M (+$21.1M)
7.11% more ownership
Funds ownership: 64.41% → 71.52% (+7.1%)
1% more funds holding
Funds holding: 72 → 73 (+1)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.1M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$8.5M |
| 3 |
Blackstone Inc
New York
|
+$4.33M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.22M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$6.77M |
| 2 |
Millennium Management
New York
|
-$2.56M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.38M |
| 4 |
FAM
Fred Alger Management
New York
|
-$1.32M |
| 5 |
Jane Street
New York
|
-$1.25M |
CMPX Hedge Fund Activity: Q2 2023 in Review
73 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2023, worth a combined $288M — up 7.9% from $267M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CMPX positions and 24 closed out — a net gain of 2 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $14.1M. The largest seller was Foresite Capital Management V, cutting an estimated $6.77M.
- 73 institutional investors held Compass Therapeutics (CMPX) as of Q2 2023, up from 72 in Q1 2023.
- Funds reported $288M of Compass Therapeutics stock for Q2 2023, up 7.9% quarter-over-quarter.
- 26 funds opened new Compass Therapeutics positions in Q2 2023 and 24 closed out, a net change of +2 holders.
- The largest Compass Therapeutics buyer in Q2 2023 was BlackRock, an estimated $14.1M added.
- The largest Compass Therapeutics seller in Q2 2023 was Foresite Capital Management V, an estimated $6.77M sold.
Based on aggregated 13F filings for Q2 2023.